Hereditary haemorrhagic telangiectasia (HHT) is diagnosed clinically by the Curaçao Criteria of spontaneous recurrent nosebleeds, mucocutaneous telangiectasia at characteristic sites, visceral ...

The FDA has approved ENCELTO, the first treatment for macular telangiectasia type 2 (MacTel), a rare degenerative eye disease that gradually impairs central vision. ENCELTO is a surgically implanted ...

Macular telangiectasia, sometimes referred to as idiopathic juxtafoveal macular telangiectasia, is a disease that affects the part of the eye called the macula, causing degradation or loss of central ...

Revakinagene taroretcel-lwey (Encelto; Neurotech), an allogeneic encapsulated cell-based gene therapy, is the first therapy to be approved for macular telangiectasia type 2.

The FDA approved Encelto, an encapsulated cell therapy, for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

Neurotech’s Encelto ™ (revakinagene taroretcel-lwey) approved by the FDA for the treatment of macular telangiectasia type 2 (MacTel). News release Neurotech Pharmaceuticals. March 6, 2025.

Access free, up-to-date clinical guidance about the clinical presentation of dermatomyositis on Healio. Our content provides valuable insights for physicians.

Telangiectasia refers to small, dilated blood vessels visible near the skin or mucous membranes' surface, often appearing on the face, legs, chest, or other areas. These vessels may be red, blue ...

Dr. Amir Bajoghli and Skin & Laser Dermatology Center are excited to introduce advanced laser treatments for telangiectasia, offering patients effective solutions to reduce the appearance of small, ...

The characteristic skin lesions are Gottron's papules: erythematous-violaceous lesions on metacarpophalangeal or interphalangeal joints, elbows or knees; shawl sign: poikiloderma in sun-exposed areas ...

Macular telangiectasia is an eye disease that leads to a loss of sharp central vision. Learn more about the symptoms, types, treatments, and more. Skip to main content ...